ArticleJournal of the American Academy of Dermatology2020
Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: A retrospective study.
Article in Journal of the American Academy of Dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- The DRESS/HLH Overlap Syndrome: A Systematic Review of Clinical Features, Triggers, and Outcomes.Journal of clinical medicine · 2026Review
- Article
- Drug reaction with eosinophilia and systemic symptoms syndrome secondary to bimekizumab.JAAD case reports · 2026Article
- Drug Reaction with Eosinophilia and Systemic Symptoms in the Electronic Medical Record.International archives of allergy and immunology · 2026Article
- A pharmacovigilance study of daptomycin use in infants under 1 year old based on the FDA adverse event reporting system.Scientific reports · 2025Article
- Article
- Article
- Rapid-onset drug reaction with eosinophilia and systemic symptoms (DReSS) in children: a scoping review.Archives of dermatological research · 2025Article
- Hypersensitivity Reactions to Iodinated Contrast Media: A Narrative Review of Current Evidence and Clinical Challenges.Healthcare (Basel, Switzerland) · 2025Review
- Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease.American journal of clinical dermatology · 2025Review
- A Rare Case of Fatal Toxic Epidermal Necrolysis (TEN) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome in a Patient with Rheumatoid Arthritis.Current drug safety · 2025Article
- Rapid-onset DRESS syndrome secondary to iopamidol contrast media with subsequent syndrome of inappropriate antidiuretic hormone secretion.JAAD case reports · 2024Article
- Symmetrical drug-related intertriginous and flexural exanthema with high-risk systemic features: a unique clinical phenotype in hospitalized patients.Archives of dermatological research · 2024Article
- Omeprazole Induced Rapid Drug Reaction with Eosinophilia, Systemic Symptoms, and Cross-Reactivity in Delayed-Type Hypersensitivity Associated with Proton-Pump Inhibitors: A Case Report and Literature Review.Case reports in immunology · 2024Article
- Renal Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review of 71 Cases.Journal of clinical medicine · 2023Review
- DRESS syndrome due to iodinated contrast media. A case report.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023Article
- Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions.The Journal of allergy and clinical immunology · 2023Review
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses.Microorganisms · 2023Review
- Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in childhood: a narrative review.Frontiers in medicine · 2023Review
- DRESS characteristics according to the causative medication.European journal of clinical pharmacology · 2022Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiagnosing drug reaction with eosinophilia and systemic symptoms (DRESS) is challenging. Some clinicians reject this diagnosis when the delay of onset is less than 15 days after drug intake.
objectivesTo assess the delay of DRESS occurrence and culprit drugs.
methodsAll patients hospitalized in 3 dermatology departments with a first occurrence of DRESS for which a drug was highly suspected were included in this retrospective study. Based on the delay in DRESS occurrence, cases were classified into 2 groups: a rapid-onset group (≤15 days after exposure) and a delayed-onset group (>15 days).
resultsA total of 41 patients with DRESS were included: 14 in the rapid-onset and 27 in delayed-onset groups. In the rapid-onset group, antibiotics (n = 6/14) and iodinated contrast media (n = 5/5) were the predominant culprits. Carbamazepine (n = 4/4), lamotrigine (n = 6/6), allopurinol (n = 8/8), and sulfasalazine (n = 2/2) were exclusively found in the delayed-onset group. LIMITATIONS: The retrospective nature, limited number of participants, and lack of detailed information on previous exposure to sensitizing drugs in some instances.
conclusionsDRESS is frequently related to drugs introduced 15 or fewer days before the occurrence of cutaneous adverse reactions. The time of onset of DRESS may differ depending on the medications involved.
Indexed as
Identifiers
31562941What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.